Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,282 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S, Kim C, Wolmark N. Paik S, et al. N Engl J Med. 2008 Mar 27;358(13):1409-11. doi: 10.1056/NEJMc0801440. N Engl J Med. 2008. PMID: 18367751 No abstract available.
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.
Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N. Paik S, et al. J Natl Cancer Inst. 2002 Jun 5;94(11):852-4. doi: 10.1093/jnci/94.11.852. J Natl Cancer Inst. 2002. PMID: 12048273
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. Paik S, et al. N Engl J Med. 2004 Dec 30;351(27):2817-26. doi: 10.1056/NEJMoa041588. Epub 2004 Dec 10. N Engl J Med. 2004. PMID: 15591335 Clinical Trial.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Romond EH, et al. N Engl J Med. 2005 Oct 20;353(16):1673-84. doi: 10.1056/NEJMoa052122. N Engl J Med. 2005. PMID: 16236738 Clinical Trial.
HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM; NCCN HER2 Testing in Breast Cancer Task Force. Carlson RW, et al. J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. J Natl Compr Canc Netw. 2006. PMID: 16813731 Review.
Anthracyclines in the treatment of HER2-negative breast cancer.
Paik S, Taniyama Y, Geyer CE Jr. Paik S, et al. J Natl Cancer Inst. 2008 Jan 2;100(1):2-4. doi: 10.1093/jnci/djm277. Epub 2007 Dec 25. J Natl Cancer Inst. 2008. PMID: 18159066 No abstract available.
Genomics of adjuvant therapy for breast cancer.
Kim SR, Paik S. Kim SR, et al. Cancer J. 2011 Nov-Dec;17(6):500-4. doi: 10.1097/PPO.0b013e31823e5370. Cancer J. 2011. PMID: 22157294 Review.
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Perez EA, et al. Breast Cancer Res Treat. 2013 Feb;138(1):99-108. doi: 10.1007/s10549-013-2444-y. Epub 2013 Feb 19. Breast Cancer Res Treat. 2013. PMID: 23420271 Free PMC article.
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S. Pogue-Geile KL, et al. J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8. doi: 10.1093/jnci/djt321. Epub 2013 Nov 21. J Natl Cancer Inst. 2013. PMID: 24262440 Free PMC article. Clinical Trial.
1,282 results
Jump to page